Related Experiment Videos
Effect of progestogens on estrogen-induced lipoprotein changes
1Department of Obstetrics and Gynecology, Uludag University Medical Faculty, Bursa, Turkey.
Summary
This study found that medroxyprogesterone acetate, used with 17 beta-estradiol therapy, does not negatively impact lipoprotein levels. HDL cholesterol significantly increased in all groups, indicating beneficial effects on lipid profiles for postmenopausal women.
Area of Science:
- Endocrinology
- Cardiovascular Health
- Pharmacology
Background:
- Estrogen therapy is used for menopausal symptoms.
- Progestogens are often co-administered with estrogen.
- The effect of progestogens on estrogen's impact on lipid profiles requires evaluation.
Purpose of the Study:
- To investigate the role of progestogens in modifying estrogen-induced changes in lipoprotein levels.
- To compare the effects of sequential and continuous progestogen regimens combined with estrogen therapy.
Main Methods:
- Sixty postmenopausal women were randomized into three groups.
- Group 1: Sequential 17 beta-estradiol and medroxyprogesterone acetate.
- Group 2: Continuous 17 beta-estradiol and medroxyprogesterone acetate.
- Group 3: Continuous 17 beta-estradiol only (hysterectomy patients).
- Lipoprotein levels (TC, HDL, LDL, TG) were measured at baseline and over 9 months.
Main Results:
- No significant changes in total cholesterol, triglycerides, or LDL cholesterol were observed in any group.
- All groups showed a significant increase in HDL cholesterol levels (P < 0.001).
- Medroxyprogesterone acetate did not counteract the positive effects of 17 beta-estradiol on HDL cholesterol.
Conclusions:
- Medroxyprogesterone acetate, in both sequential and continuous use, does not oppose the beneficial effects of transdermal 17 beta-estradiol on lipoprotein profiles.
- Transdermal estrogen therapy, even with progestogen add-back, favorably impacts HDL cholesterol levels in postmenopausal women.